Información del artículo
El Texto completo está disponible en PDF
Bibliografía
[1.]
K. Shiomi.
Discovery of new macrolides.
Macrolide antibiotics, pp. 1-56
[2.]
A. Kucers, S. Crowe, M.L. Grayson, J.F. Hoy.
The use of antibiotics.
[3.]
G. Zhanel, M. Dueck, D.J. Hoban, L.V. Vercaigne, J.M. Embil, A.S. Gin.
Review of macrolides and ketolides.
Drugs, 61 (2001), pp. 443-498
[5.]
H. Nadler, M. Dowzicky, C. Feger, M.R. Pease, P. Prokocimer.
Quinupristin/dalfopristin: A novel selective-spectrum antibiotic for the treatment of multi-resistant and other Gram-positive pathogens.
Clin Microbiol Newsletter, 21 (1999), pp. 103-112
[6.]
F. Namour, D. Wessels, P. Reynolds, E. Sultan, B. Lenfant.
Pharmacokinetics of the new ketolide telithomycin (HMR 3647) administered in ascending single and multiples doses.
Antimicrob Agents Chemother, 45 (2001), pp. 170-175
[7.]
C. Carbon.
Pharmacodynamics of macrolides, azalides and streptogramins: Effect on extracellular pathogens.
Clin Infect Dis, 27 (1998), pp. 28-32
[8.]
C. Carbon.
Clinical relevance on intracellular and extracellular concentrations of macrolides.
Infection, 23 Suppl 1 (1995), pp. 10-14
[9.]
D. Morris, A. De Souza, A. Jones, W. Morgan.
High and prolonged pulmonary tissue concentrations of azithromycin following a single oral dose.
Eur J Clin Microbiol Infect Dis, 10 (1996), pp. 859-861
[10.]
M. Bergeron, G. Montay.
The pharmacokinetics of quinupristin/dalfopristin in laboratory animals and in humans.
J Antimicrob Chemother, 39 (1997), pp. 129-138
[11.]
J. Mensa, J.M. Gatell, M.T. Jiménez de Anta, G. Prats.
Guía de Terapéutica Antimicrobiana.
[12.]
D.R. Guay, L.E. Gustavson, K.J. Devcich, J. Zhang, G. Cao, C.A. Olson.
Pharmacokinetics and tolerability of extended-release clarthromycin.
Clin Ther, 23 (2001), pp. 566-577
[13.]
J. Williams, A. Sefton.
Comparison of macrolides antibiotics.
J Antimicrob Chemother, 31 Suppl C (1993), pp. 11-26
[14.]
E. Eisenberg, M. Barza.
Azithromycin and clarithromycin.
pp. 52-79
[15.]
D. Schlossberg.
Azithromycin and clarithromycin.
Med Clin North Am, 79 (1995), pp. 803-815
[16.]
L. Dever, J. Jorgensen, A. Barbour.
Comparative in vitro activities of clarithromycin, azithromycin, and erythromycin against Borrelia burgdorferi.
Antimicrob Agents Chemother, 37 (1993), pp. 1704-1706
[17.]
J. Hamilton-Miller.
In vitro activities of 14, 15 and 16 membered macrolides against gram-positive cocci.
J Antimicrob Chemother, 29 (1992), pp. 141-144
[18.]
R. Landínez, J. Liñares, E. Loza, J. Martínez-Beltrán, R. Martín, F. Baquero.
In vitro activity of azitromycin and tetracycline against 358 clinical isolates of Brucella melitensis.
Eur J Clin Microbiol Infect Dis, 11 (1992), pp. 265-267
[19.]
G.W. Amsden.
Pneumococcal macrolide resistance-myth or reality?.
J Antimicrob Chemother, 44 (1999), pp. 1-6
[20.]
D. Felmingham, G. Zhanel, D. Hoban.
Activity of the ketolide antibacterial telithromycin against typical community-acquired respiratory pathogens.
J Antimicrob Chemother, 48 (2001), pp. 33-42
[21.]
G. Archer, P. Auger, G. Doern, M.J. Ferraro, P.C. Fuchs, J.H. Jorgensen.
RP59500, a new streptogramin highly active against recent isolats of North America staphylococci.
Diagn Microbiol Infect Dis, 16 (1993), pp. 223-226
[22.]
A.L. Barry, P.C. Fuchs, S.D. Brown.
Provisional interpretive criteria for quinupristin/dalfopristin susceptibility test.
J Antimicrob Chemother, 39 Suppl A (1997), pp. 87-92
[23.]
S. Douthwaite, W. Champney.
Structures of ketolides and macrolides determine their mode of interaction with the ribosomal target site.
J Antimicrob Chemother, 48 (2001), pp. 1-8
[24.]
S. Douthwaite.
Structure-activity relationships of ketolides vs. macrolides.
Clin Microbiol Infect, 7 Suppl 3 (2001), pp. 11-17
[25.]
A. Canu, R. Leclercq.
Overcoming bacterial resistance by dual target inhibition: The case of streptogramins.
Current Drug Targets, 1 (2001), pp. 215-225
[26.]
R. Goldman, S. Fesik, C. Doran.
Role of protonated and neutral forms of macrolides in binding to ribosomes from gram-positive and gram-negative bacteria.
Antimicrob Agents Chemother, 34 (1990), pp. 426-431
[27.]
I. Odenholt, E. Lowdin, O. Cars.
Pharmacodynamics of telithromycin in vitro against respiratory tract pathogens.
Antimicrob Agents Chemother, 45 (2001), pp. 23-29
[28.]
M. Labro, J. Benna, H. Abdelghaffar.
Modulation of human polymorphonuclear neutrophil function by macrolides: Preliminary data concerning dirithromycin.
J Antimicrob Chemother, 31 Suppl C (1993), pp. 51-64
[29.]
R. Mizukane, Y. Hirakata, M. Kaku, Y. Ishii, N. Furuya, K. Ishida.
Comparative in vitro exoenzyme-suppresing activities of azithromycin and other macrolide antibiotics against Pseudomonas aeruginosa.
Antimicrob Agents Chemother, 38 (1994), pp. 528-533
[30.]
R. Howe, R. Spencer.
Macrolides for the treatment of Pseudomonas aeruginosa infections?.
J Antimicrob Chemother, 40 (1997), pp. 153-155
[31.]
R. Leclercq.
Overcoming antimicrobial resistance: Profile of a new ketolide antibacterial, telithromycin.
J Antimicrob Chemother, 48 (2001), pp. 9-23
[32.]
R. Leclercq, P. Courvalin.
Bacterial resistance to macrolide, lincosamide, and streptogramin antibiotics by target modification.
Antimicrob Agents Chemother, 35 (1991), pp. 1267-1272
[33.]
M. Liu, S. Douthwaite.
Activity of the ketolide telithromycin is refractory to erm monomethylation of bacterial rRNA.
Antimicrob Agents Chemother, 46 (2002), pp. 1629-1633
[34.]
K. Gay, W. Baughman, Y. Miller, D. Jackson, C. Whitney, A. Schuchat.
The emergence of Streptococcus pneumonie resistant to macrolide antimicrobial agents: A 6-year population-based assesment.
J Infect Dis, 182 (2000), pp. 1417-1424
[35.]
F. Baquero, J.A. García, de Lomas. García.
Antimicrobial resistance of 914 beta-hemolytic streptococci isolated from pharyngeal swabs in Spain: Results of a 1-year (1996-1997) multicenter surveillance study.
Antimicrob Agents Chemother, 43 (1999), pp. 178-180
[36.]
C. Betriu, E. Culebras, M. Redondo, I. Rodríguez-Avial, M. Gómez, A. Boloix.
Prevalence of macrolide and tetracycline resistance mechanims in Streptococcus pyogenes isolates and in vitro susceptibility to telithromycin.
J Antimicrob Chemother, 50 (2002), pp. 436
[37.]
H. Neu, L. Young, S. Zinner, J. Acar.
New macrolides, azalides, and streptogramins in clinical practice.
[38.]
S. Zinner, L. Young, J. Acar, H. Neu.
Expanding indications for the new macrolides, azalides, and streptogramins.
[39.]
S. Schonwald, V. Skerk, I. Petricevic, V. Car, M. Misic, M. Gunjaka.
Comparison of three-day and five-day courses of azithromycin in the treatment of atypical pneumonia.
Eur J Clin Microbiol Infect Dis, 10 (1991), pp. 877-880
[40.]
P. Gleason, T. Meehan, J. Fine, D. Galusha, M. Fine.
Associations between initial antimicrobial therapy and medical outcomes for hospitalized elderly patients with pneumonia.
Arch Intern Med, 159 (1999), pp. 2562-2572
[41.]
J. Stahl, M. Barza, J. Desjardín, R. Martín, M. Eckman.
Effect of macrolides as part of initial empiric therapy on length of stay in patients hospitalized with community-acquired pneumonia.
Arch Intern Med, 159 (1999), pp. 2576-2580
[42.]
H. Handsfield, Z. Dalu, D. Martin, J. Douglas, J. McCarty, D. Schlossberg.
Multicenter trial of single-dose azithromycin vs. ceftriaxone in the treatment of uncomplicated gonorrhea.
Sex Transm Dis, 21 (1994), pp. 107-111
[43.]
N. Girgis, T. Butler, R. Frenck, Y. Sultán, F. Brown, D. Tribble.
Azitromycin versus ciprofloxacin for treatment of uncomplicated typhoid fever in a randomized trial in Egypt that included patients with multidrug resistance.
Antimicrob Agents Chemother, 43 (1999), pp. 1441-1444
[44.]
L. Jackson, D. Stewart, S. Wang, D. Cooke, T. Cantrell, T. Grayston.
Safety effect on anti-Chlamydia pneumoniae antibody titres of a 1 month course of daily azithromycin in adults with coronary artery disease.
J Antimicrob Chemother, 44 (1999), pp. 411-414
[45.]
A. Stone, M. Mendall, J.C. Kaski, T. Edger, P. Risley, J. Poloniecki.
Effect of treatment for Chlamydia pneumoniae and Helicobacter pylori on markers of inflamation and cardiac events in patients with acute coronary syndromes: South thames trial of antibiotics in myocardial infarction and unstable angina (STAMINA.
Circulation, 106 (2002), pp. 1219-1223
[46.]
H. Yassim, L. Dever.
Telithromycin: A new ketolide antimicrobial for treatment of respiratory tract infections.
Expert Opin Investig Drugs, 10 (2001), pp. 353-367
[47.]
Fagon JY for the Global Synercid? NP Study Group. Randomized, comparative, multicenter, open study of quinupristin/dalfopristin plus aztreonam versus vancomycin plus aztreonam in the treatment of Gram-positive nosocomial pneumonia. Proceedings of the 20th International Congress of Chemotherapy (ICC); 1997 June 29-July 3; Sydney, Australia
[48.]
Nichols R for the Global Quinupristin/Dalfopristin SSSI Study Group. Randomized, comparative, multicenter, open study of quinupristin/dalfopristin in the treatment of complicated Gram-positive skin and skin structure infections (C-SSSI). Proceedings of the 20th International Congress of Chemotherapy (ICC); 1997 June 29-July 3; Sydney, Australia
[49.]
R.L. Nichols, D.R. Graham, S.L. Barriere, A. Rodgers, S.E. Wilson, M. Zervos.
Treatment of hospitalized patients with complicated Gram-positive skin and skin structure infection: Two randomized, multicentre studies of quinupristin/dalfopristin versus cefazolin, oxacillin or vancomycin.
J Antimicrob Chemother, 44 (1999), pp. 263-273
[50.]
R.C. Moellering.
Quinupristin/dalfopristin: Therapeutic potencial for vancomycin-resistant enterococcal infections.
J Antimicrob Chemother, (1999), pp. 25-30
[51.]
J.C. Péchère.
Current and future management of infections due to methicillin-resistant staphylococci infections: The role of quinupristin/dalfopristin.
J Antimicrob Chemother, 44 (1999), pp. 11-18
Copyright © 2003. Elsevier España, S.L.. Todos los derechos reservados
